With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
The protective effects of diet modification, exercise, and other lifestyle changes against new-onset diabetes showcased in the three-year Diabetes Prevention Program continued out to 10 years in a follow-up analysis.
Bethesda,MD - A number of prospective studies have shown that behavioral and lifestyle interventions can provide lasting protection against new type 2 diabetes in people at increased risk, but the question remains: For how long?
What might be the longest follow-up yet of patients from such a randomized controlled trial comes this week from the DiabetesPreventionProgram (DPP) research group, which saw protective effects of both lifestyle intervention and treatment with metformin last as long as 10 years [1].Read full article »
Inside: Lipid/Metabolic
Accredited educational programs,
supported by industry, developed by theheart.org
Reducing CV Risk: What Add-On Therapies Do You Use? Click to take the survey and compare answers. The results will help us create future CME programming
How will the results of JUPITER expand the universe of cardiovascular risk evaluation? Join Drs Ballantyne, Ridker, and Chapman as they discuss this important biomarker study and its implication for clinical practice.
Join Drs. Blumenthal and Ridker as they inform our community about upcoming consensus guidelines which will address this current medical debate, as well as the limitations of existing treatments as they formulate their management strategies.
SANDS: Join Drs. Lonn and Howard as they share their views and discuss the clinical implications of the latest controversial findings on statin therapies and aggressive targeting aimed at reducing atherosclerosis and CVD
Join our panel of experts, Drs Ridker, Blumenthal, Ballantyne, and Wilson as they discuss the pathophysiology of inflammation as it relates to the development and progression of CVD and how systemic inflammation biomarkers can be used as surrogate endpoints in clinical trials of therapeutic agents.
The JUPITER trial showed that rosuvastatin was superior to placebo in reducing hard endpoints in apparently healthy people with low or normal LDL levels but elevated C-reactive protein (CRP). Join Drs Genest, Ridker, Tardif, and Gupta as they discuss the implication of these findings on current practice.
The syndrome (defined by ATP III criteria) can predict increased cardiovascular and mortality risk or not, depending on which three of five risk factors contributed to the diagnosis, a cohort study suggests; its investigators caution that their observations are only preliminary.
The imaging study was the first to show that stenting a non-flow-limiting stenosis of an SVG may help slow or halt the accelerated atherosclerosis that takes place in these vessels. An accompanying editorial cautions that the study does little more than "infer a trend toward anatomic benefit."
More discussion about the J-curve in hypertension is published this week; one expert believes the undue attention being paid to this subject might discourage doctors from treating high blood pressure aggressively.
UPDATED // An 1126-patient trial shows that SPECT and CAC scoring imaging tests are independent and complementary predictors of short- and long-term cardiac risk, respectively.
The FDA has issued a warning about exenatide the same day the agency approved its first-line use along with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
Statins for heart failure? After they failed to show much effect in two large randomized trials? Yesmaybe; at least in patients with ischemic heart failure who start the drugs early enough, suggests a post hoc analysis based on one of the trials.
Just weeks before ARBITER-HALTS 6 results come out at AHA 2009, an MRI study suggests that niacin is better than placebo in statin-treated patients with low HDL, at least for reducing carotid wall area. Experts say they'd also like to see insights into niacin effects on lipid-rich plaque volumesthe more commonly seen end point with MRI.
A new analysis from the Northern Manhattan Study finds that high-sensitivity C-reactive protein was modestly associated with mortality and MI but not ischemic stroke in this multiethnic population, suggesting the predictive value may depend on other factors.
Two well-known observational registries highlight such changes in women and men over a decade or more: Do women younger than 55 still have an advantage over men in the same age group?
Raised in a blue-collar neighborhood of Somerville, MA, Dr Bob Harrington was blessed to have a strong family and the Jesuits on his side as he traveled from "Yankee" Boston to Duke University. Join him as he tells his story to Dr Rob Califf.
How do regulatory pathways differ in the US and UK? Drs Harrington, Bhatt, and Cleland share their experiences and offer insight on how to support innovative research.
With the ISIS-1 trial, Dr Peter Sleight and his team at Oxford changed the approach to cardiovascular research. Join Dr Robert Califf as he talks to Dr Sleight about his journey from London to San Francisco to Oxford and finally to Italy, where he discovered the music of the heart.